Latest SGTX reports update at 2023-08-07: 2023-Q2 ∙ 2023-Q1 ∙ 2022-Q4

Sigilon Therapeutics SGTX

$ 22.47 0.0%

Sigilon Therapeutics Balance Sheet 2011-2024 | SGTX

Annual Balance Sheet Sigilon Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-25.6 M	-83.9 M	-177 M	-51 M	-59.1 M	-	-	-	-	-	-	-
Long Term Debt	12 M	18.4 M	19.8 M	14.9 M	4.29 M	-	-	-	-	-	-	-
Long Term Debt Current	4.48 M	4.84 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	31.9 M	128 M	74.6 M	-	-	-	-	-	-	-
Total Current Liabilities	31 M	34.9 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	48.1 M	67.2 M	78.9 M	168 M	104 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	31.8 M	29.1 M	24.7 M	-	-	-	-	-	-	-
Retained Earnings	-257 M	-213 M	-136 M	-81.3 M	-37.4 M	-	-	-	-	-	-	-
Total Assets	87.3 M	144 M	225 M	90.4 M	67.7 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	42.1 M	107 M	203 M	-	-	-	-	-	-	-	-	-
Book Value	39.1 M	77.2 M	146 M	-77.8 M	-36.1 M	-	-	-	-	-	-	-
Total Shareholders Equity	39.1 M	77.2 M	146 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Sigilon Therapeutics

	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	2.86 M	10.4 M	12 M	13.6 M	-	16.8 M	18.4 M	20 M	20 M	20 M	19.8 M	20 M	20 M	20 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	28.1 M	43.3 M	48.1 M	50.2 M	-	61.6 M	67.2 M	70.5 M	75.1 M	74.4 M	78.9 M	78.9 M	78.9 M	78.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-272 M	-264 M	-257 M	-250 M	-	-227 M	-213 M	-195 M	-175 M	-155 M	-136 M	-136 M	-136 M	-136 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	55.6 M	76.6 M	87.3 M	94.6 M	-	126 M	144 M	164 M	186 M	203 M	225 M	225 M	225 M	225 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	19.6 M	41.3 M	42.1 M	32.9 M	35.9 M	161 M	107 M	142 M	162 M	179 M	202 M	202 M	202 M	202 M	76.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	27.4 M	33.3 M	39.1 M	44.4 M	-	64.6 M	77.2 M	93.3 M	111 M	129 M	146 M	146 M	146 M	146 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	27.4 M	33.3 M	39.1 M	44.4 M	51.8 M	64.6 M	77.2 M	93.3 M	111 M	129 M	146 M	146 M	146 M	146 M	-77.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency